TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vectus Biosystems Limited ( (AU:VBS) ) just unveiled an update.
Vectus Biosystems Limited held its Annual General Meeting on November 26, 2025, where all proposed resolutions were passed. These included the re-election of Ronald Shnier as a director, the election of Linda Walters as a director, and the adoption of the remuneration report. The successful passing of these resolutions indicates strong shareholder support and may positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited operates in the biotechnology industry, focusing on developing therapeutic treatments for fibrosis and high blood pressure-related disorders. The company is dedicated to advancing its proprietary technology to address unmet medical needs in these areas.
Average Trading Volume: 88,110
Technical Sentiment Signal: Hold
Current Market Cap: A$10.4M
Learn more about VBS stock on TipRanks’ Stock Analysis page.